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1. Introduction 
1.1 Etiopathogenesis 
Bovine respiratory disease (BRD) complex is a major disease, classically in the indoor calves 
and feedlot young cattle. The etiopathogenesis of BRD is multifactorial and complex. In this 
complex etiology an equivalent role plays both the infectious agents  as well as the 
environmental factors which are called also as environmental stressors (inappropriate 
livestock management like mistakes in animal nutrition, transport, handling, veterinary 
interventions etc.) (tab. 1). The most significant pathogens which are involved in the 
etiopathogenesis of BRD, i.e. suitable species of viruses such as (bovine respiratory syncytial 
virus (BRSV), parainfluenza virus type 3 (PI3V), bovine herpes virus type 1 (BHV1), bovine 
viral diarrhea virus (BVDV), are usually associated with concurrent bacterial infections 
represented by: Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and others 
(tab. 1) (Jared et al., 2010a, Kita et al., 1994, Klimentowski et al., 1995) and also mycoplasmal 
factors such as: Mycoplasma bovis, Mycoplasma bovirhinis, Mycoplasma dispar, Ureaplasma 
diversum and even Mycoplasma canis (Szymańska et al., 2010). Among bacteria M. haemolytica  
and P. multocida have been traditionally considered as the most common bacterial infectious 
factors in the BRD etiology (Fulton et al.; Reggiardo et al., 2005). On the other hand the one 
of the most often isolated mycoplasmal factors from BRD cases is Mycoplasma bovis. Its 
adaptative ability to a host organism increases owing to different versions of the same vsp 
gene family which encode particular adhesive factors of the mycoplasma, i.e. variable 
surface proteins (Vsps; Razin et al., 1998). The variability of vsp gene based on DNA 
transposition (Lysnyansky, 1996). Therefore the high Vsp variation determines the 
phenotypic variability of the antigen (Rosengarten et al., 1994) which further increases the 
virulence of the pathogen. M. bovis possess the ability to immunomodulate host defence 
against infection (Razin et al., 1998), for example inducing a synthesis of proinflammatory 
agents, i.e. TNF-α and nitric oxide (Jungi, et al., 1996) or stimulation of some acute phase 
protein production, such as haptoglobulin and serum amyloid A, which represent one of the 
most important components of acute phase response for cattle (Dudek, 2010). It is known 
that M. bovis acts as a stimulant on major subsets of T-lymphocytes (Vanden Bush, 2003). In 
contrast, some data show inhibitory properties of the pathogen which come down to its 
suppressive effect on lymphocytes (Vanden Bush & Rosenbusch, 2002; Thomas et al., 1990) 
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and some neutrophil functions (Thomas, et al. 1991). The inhibitory effect of M. bovis on the 
mononuclear cells is not connected with arginine depletion or cytotoxic activity (Thomas et 
al., 1990). Recently, M. bovis is considered as primary pathogen in BRD, not only acting in 
coinfection conditions. The significance of M. bovis in etiopathogenesis of the syndrome is 
also important with regard to synergistic effect with some infectious factors involved in 
BRD. For example, M. bovis exhibits the colonising synergism with Mannheimia haemolytica 
(Houghton & Gourlay, 1983), whereas coinfection with bovine viral diarrhea virus (BVDV) 
may increases a pathogenicity of concomitant infectious agents mainly considering 
suppression of host immune response (Potgieter, 1997; Haines et al., 2001). The disease 
course during infection with M. bovis is generally acute and relates to young cattle (Wikse, 
1985). Clinical symptoms mainly limited to dysfunction of the respiratory tract of animals, 
including cases of fatal diseases, and their intensity decreases with the development of 
chronic phase of infection (Nicholas & Ayling, 2003). However, complicated infections with 
M. bovis have usually severe course and may take the form of necrosuppurative 
bronchopneumonia. Pathological changes of the disease are characterized by consolidation 
areas with nodular lesions containing necrosuppurative material surrounded with fibrous 
capsule, whereas in histology they are rich in foci infiltrated by degenerating leukocytic cells 
(Radaelli et al., 2008).  
Stress factors Viruses Bacteria 
Heat 
Cold 
Dust 
Dampness 
Injury 
Fatigue 
Dehydration 
Hunger 
Anaxiety 
Irritant gases 
Nutrional 
deficiencies 
Surgery 
Bovine respiratory syncytial virus 
(BRSV) 
Parainfluenza virus type 3 (PI3) 
Bovine herpes virus type 1 (BHV)) 
Bovine viral diarrhoea virus (BVDV) 
Adenoviruses 
Rhinovirus 
Enteroviruses 
Bovine respiratory coronavirus 
 
Mannheimia haemolytica 
P. multocida 
Histophilus somni 
Arcanobacterium pyogenes 
Streptococcus pneumonie 
Staphylococcus aureus 
Chlamydiales spp. 
Fusobacterium necrophorum 
Corynebacterium bovis 
Streptococcus spp. 
Micrococcus spp. 
 
Mycoplasmas 
M. bovis 
M. bovirhinis 
M. dipsar 
M. alkalesscens 
M. canis 
M. bovigenitalium 
Ureaplasma spp. 
Ureaplasma diversum 
Table 1. The most important etiological causes of BRD 
In the complex etiology of BRD also other mycoplasmas, such as M. dispar, M. bovirhinis or 
U. diversum  can play an important role (Autio et al., 2007). These mycoplasma species were 
concurrently present in 50% of examined herds and bacterial agents of the syndrome, i.e. P. 
multocida, Arcanobacterium pyogenes or M. haemolytica coexisted with these cases. 
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Additionally, main viruses of bovine respiratory system were concomitant factors of the 
infections. However, the highest correlation between the prevalence and clinical respiratory 
signs of disease were observed for U. diversum when compared with M. dispar and M. 
bovirhinis (Autio et al., 2007).  
In the chronic form of the respiratory syndrome should be also mention about chlamydia, 
particularly Chlamydophila psittaci and Ch. pecorum apart from that anaerobes bacteria such 
as Clostridium sp. are often engaged in the etiopathogenesis of the disease. Moreover, the 
different endogenous factors play also an important etiological role in the BRD etiology. 
First of all young cattle before one - year - old have an insufficient developed respiratory 
system for an efficient gas exchange and fully effective and constructive mucociliary 
clearance mechanisms. Calves have almost by a half lower of the lung surface for gas 
exchange and higher primary activity of pulmonary ventilation, which in connection with 
the increased of metabolic demand in these animals is the main cause of low supply of 
oxygen in the body. The low partial pressure of oxygen causes a significant weakening of 
the movement of cilia snapshot, phagocytic activity of pulmonary macrophages and a 
reduction in lung clearance of harmful microorganisms. When an affectivity of pulmonary 
clearance and local immune response of the lungs are reduced, a variety of infectious agents 
(viruses, bacteria, mycoplasmas) have better access to lower parts of the respiratory tract 
and they can initiate the development of pathological lesions (Lekeux  et al., 1995). 
While the different pathogens involved in  etiology of BRD are presented in the heard 
throughout the years, the outbreak of the disease and an appearance of clinical symptoms 
are seasonal. Usually, there are two seasonal peaks of enzootic pneumonia occurred: the first 
was between October and December and the second from February to May (Andrews, 
2004). The sigs of the disease depend on its clinic form i.e. chronic or acute. The chronic form 
of BRD generally shows no signs. The calves are bright, eats well but may have a slight 
mucoid or mucopurulent oculonasal discharge, the body temperature is normal or slightly 
raised at 38.5-39.5°C and dry, explosive cough usually is produced singly. During the acute 
case of the disease inappetance, pyrexia (40-42°C), dull sweaty coat, mucoid and 
mucopurulent oculo-nasal discharge, tachypnoea (respiratory rate- RR over 40 breaths per 
minute) are presented. Moreover, there is a tendency to a persistent coughing. The cough 
can be harsh, dry, hacking type but sometimes is moist. During the auscultation of the 
thorax under both inspiration or expiration there are loud, harsh sounds or whistling, 
wheezing or squeaking (Andrews, 2004). 
At present, BRD is a great economic problem in cattle husbandry, especially in young and 
feedlot animals all over the world. It accounts for approximately 30% of the total cattle 
deaths worldwide and is associated with an annual economic losses of over one billion 
dollars in North America alone (Adamu, 2007). However, the most often outbreak of acute 
disease occurs when there are calves from different sources in herds. The congestion and 
inadequate ventilation are the predisposing factors for the development of BRD. Despite 
that the different pathogens cause of BRD its initial clinical symptoms are very similar i.e. 
bronchitis and bronchiolititis. In the first phase of the disease the mucus production in 
diseased calves increases and its stand over in respiratory tract. This is cause a main cause 
for handicap of defence mechanism in the course of the respiratory disease and the spread 
of bacterial infections in lungs, which resulted in the intensification of the primary viral 
infections. The studies recently conducted in Poland have been found the mixed viral 
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 366 
infections in field outbreaks of BRD (Kita et al., 1994). The highest specific antibody titres 
were detected particularly in relation to: BRSV, BHV-1, BVDV, PI-3 and Adeno-3.  
During the necropsy the anatomicopathologic changes are observed in the ventral part of 
the lung lobes and involve, in the decreasing the apical, cardiac and cranial part of the 
caudal lobes. The area can involved 5 - 40% of the lung tissue. Histologically, the changes  
concerning intensive accumulations of lymphocytes in the peribronchiolar tissue are usually 
found, macroscopically it is seen as a mottling of the lesion’s cut surface. In the acute 
pneumonia there are three types of pathological changes. Type 1- pulmonary tissue 
consolidation - is noted in the cranial lobes of lungs and the tissue is dark red, friable and 
there is no necrosis changes. The type 2 – in a form of the  marked consolidation  is very 
often observed in cranial lobes too with red/grey hepatisation, necrosis and suppuration. 
The extensive consolidation and suppuration are seen during A. pyogenes and F. necrophorum 
infections. The 3th type of pathological entity is characteristic for calves that suddenly 
developed respiratory diseases. In this case there is interstitial emphysema, pulmonary 
oedema and congestion with alveolar epithelia hyperplasia and hyaline membrane 
formation (Andrews, 2004). 
Viruses are believed to predispose to bacterial infections in two distinct ways. The first, viral 
agent can cause direct damage to the respiratory clearance mechanism and translocation of 
bacteria from the upper respiratory tract. The second way, viral infection can interfere with 
the immune system’s ability to respond to bacterial infections. The viruses can affect the 
leukocytes causing impairment of their function which result in increased susceptibility to 
infection of Mannheimia haemolytica (Jared et al., 2010a). The virus which seen to be the most 
often responsible for the appearance of BRD is BVD/MD. The virus may suppress the 
immune system in the affected animals. The infection of BVD/MD leads to inhibition the 
production of interferon, a decline in the number of leukocytes and the weakening of 
humoral immunity by reducing production of antibodies it causes bacterial infections 
(Polak, M., 2008). 
The clinical cases which confirmed the presence of Mannheimia haemolytica have a sever 
character and finishing quick death (Bednarek, 2010). In sick animals are usually found high 
fever, mucopulurent or pulurent nasal discharge, lacrimation, incidence of painful cough 
with symptoms of severe shortness of breath, weakness and apathy. In some animals may 
have been presented watery diarrhea and ill animals not shown willingness to foraging. As 
a result of this pathogen infection in affected animals occur the extensive damage and 
inflammation of lung tissue. M. haemolytica produces many other potentially virulent factors, 
among them leukotoxin (Lkt; Hinghlander, 2001; Whitley et al., 1992). The leukotoxin 
izoform produced by M. haemolytica biotype A, serotype 1, has the most visible cytotoxic 
proprieties in relation to bovine leukocytes. It has been discovered that bovine leukocytes 
exposed to low doses of exotoxin show reduced phagocytic and killing activity engulfed 
bacteria. On the other hand, higher concentration of the agent causes complete destruction 
of the leukocytes leading to their swelling and bursting (Clinkenbeard et al., 1989; Bednarek 
et al., 2009). The Lkt binds specific leukocyte adhesion molecules, signal-inducing trans-
membrane pore formation is generated, leading to efflux of K+, influx of Ca2+(Clinkenbeard 
et al., 1989). Many potentially profitable reactive substances  (free radicals, lizosomal 
enzymes, proteases) in relation to phagocytes (netrophils, monocytes) are realised from the 
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destroy cells and then they stimulate different pathological lesions in host affected lung 
tissue. The process manifested with an acute lobar fibrionecrotising pneumonia. This 
histopathological picture is characteristic for acute BRD. All the changes are consequences of 
Lkt action and the development of lung inflammatory cascade regulated additionaly by 
some pro-inflamatory cytokines (Bednarek et al., 2009). The clinical cases in which the M. 
haemolityca is included have severe clinical courses. According to the literature the 
intravenous administration of M. haemolytica A1 leukotoxin to clinically healthy calves 
caused the occurrence of the leukopenia manifested with the significant decrease of total 
peripheral WBC count with lower values of polymorphonuclear leukocyte and MID cell 
percentages, the last is a total value of  all blood peripheral monoctes, eosinophils and  
basophils. Moreover, there were significant changes regarding some lymphocyte 
subpopulations such as: CD2+ (T lymphocytes), CD4+ (T helper lymphocytes) and CD8+ 
(supresor/cytotoxic lymphocytes). The leukopenia resulted from the toxic influence of M. 
haemolytica A1 Lkt, demonstrating a species-specyfic depletion effect with respect to bovine 
leukocytes (Bednarek et al., 2008). Additionally, the concentrations of some acute phase 
proteins (CRP, Cp, Tf, Hp, SAA and also eicosanoids (PGE2, PGF2α, LTB4) had also 
significantly changes, because there were their higher values after administration of 
leukotoxin (Bednarek et al.,  2009, 2010). 
2. Diagnosis 
The initial viral or mycoplasmal diseases are usually mild and are clinically distinguishing. 
The syndrome can be form subclinical to acute; most are somewhere in between. The initial 
viral/mycoplasmal diseases causes a moderate fever, sometimes accompanied by 
constipation. This is followed by rhinitis with a serous-to-mucopulurent discharge and 
pneumonia with a harsh, hacking cough, tachypnea, dyspnea and diarrhea. The calves very 
often are depressed, listless and anorectic. The bacterial infection causes intensity these sigs, 
with higher fevers, more severe dyspnea and depression and sigs of toxaemia. Calves are 
particularly difficult to auscult and abnormal lungs sounds may be hard to detect. In cases 
with severe consolidation, the normal breath sounds are replaced by harsh, high-pitched, 
large airway noises in the anterior-ventral lung fields. When secondary infection with 
Pasteurella multocida occurs the temperature rise to 41 -41.5°C, the area of lung affected is 
much increased, and increased breath sounds due to congestion are followed by pleuritic 
friction rub. The acute course is 10 to 14 days. The differential diagnoses should include 
aspiration pneumonia from improper tubing or feeding practices and purely viral 
pneumonias such as those caused by IBR, BVD and bovine respiratory syncytial virus 
(Blood et al., 1983; Smith, 1990). 
The laboratory diagnostics of BRD is directly connected with an isolation and identification 
of suitable species of viruses, bacteria or mycoplasmas presented in a sample tested. These 
methods are in the various cases the same or similar, but some are specific to a given agent. 
However, at present the routine diagnostics is divided into two parts. The first one mainly 
consist of serological methods and the second is nowadays dominated by the molecular 
biology (PCR and real time-PCR). In the intravital diagnostic process an usual material 
collected is the nasal swabs or lung lavages and sera samples. On the other hand, post-
mortem there are collected tissue samples from lungs and parenchymatous organs (liver, 
kidneys, spleen). The random amplified polymorphic DNA polymerase chain reaction 
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(RAPD-PCR) found excellent correlation between lung and nasal isolates. The nasal 
passages of sick animals may provide clues as to what strain is present in the lung (Jared et 
al., 2010b).  
In the diagnosis of mycoplasmal infection there are used both microbiological, serological 
and molecular biology methods. It is worth mentioning that mycoplasmas need specific 
media (Eaton’s or Hayflik’s medium) and suitable conditions to grow, i.e. 37ºC and 5% of 
CO2. Mycoplasma culture methods were also described by Autio et al. (Autio et al., 2007). 
A characteristic feature of mycoplasmas is their growth on solid media in the form of 
„fried eggs” (Miles, 1998). Some species of mycoplasmas such as M. bovis have the ability 
to create spot and film reactions and the latest increase their resistance to adverse 
environmental conditions during culture. In order to diversify the presence of 
mycoplasmas and bacteria in the material from culture microscope method by Diens’s 
was applied. In this method, mycoplasmal colonies are visible due to their ability to 
absorb dye (Malinowski & Kłossowska, 2002). Polymerase Chain Reaction (PCR) and its 
modification - real-time PCR (rt-PCR) are the techniques for identifying mycoplasmas 
from biological material (Sachse et al. 2010; McAuliffe et al., 2005; Miles et al., 2004; 
Vasconcellos et al., 2000) but they have some limitations. Technique which is devoid of 
these limitations is denaturing gradient gel electrophoresis (DGGE) that allows 
differentiation of sixty seven mycoplasma species from one sample, including thirteen 
bovine pathogens in this M. bovis, M. dispar, M. bovirhinis and M. canis (McAuliffe et al., 
2005). However, to detect the presence of anti-mycoplasma antibodies in sera samples 
there were applied ELISA tests (Ghadersohi, 2005; Bansal et al., 1995).  
The diagnosis of bacterial infections involved in BRD is based on many species-specific 
methods, such as conventional bacterial cultivation (Autio et al. 2007, Angen et al., 1998), 
phenotyping characterization (Angen et al., 2002), indole reaction (Autio et al., 2007) or 
molecular biology techniques. From the latest a PCR method was applied for main bacterial 
agents of the syndrome, such as P. multocida (Miflin & Blackall 2001), M. haemolytica (Angen  
et al., 2009) or H. somni (Angen et al., 1998).  
In order to identify viral infections in the respiratory syndrome there are used methods 
detecting the presence of both antigens and specific antibodies. An antigen of some virus 
species, such as BVDV, BHV1, PIV-3 or BRSV can also be identified using isolation test or 
Elisa methods (Uttenthal et al., 1996; Autio et al., 2007). From molecular biology techniques 
to identify the viruses species-specific PCR and rt-PCR methods were applied (Autio et al., 
2007; Vilcek et al., 1994). However, the presence of specific anti-viral antibodies in sera 
samples is possible to detect using Elisa techniques (Anderson et al., 2011) and others.  
3. Control 
The control of Bovine respiratory disease (BRD) mainly based on therapeutic management 
because of its multifactorial etology past prophylactic measures, including different 
vaccination programmes with using both mono- and polyvalent inactivated or modified live 
vaccines are not sufficiently effective till now. Therefore, at present new advanced, mostly 
complex - adjunctive therapeutic strategies are widely recommended in order to minimise 
the economic impact of the respiratory syndrome. According to the generally accepted 
opinion preferred by Pierre Lekeux (2006), i.e. a very known international expert in this 
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discipline, the fully effective BRD system of treatment should be included three independent 
steps and the system could be called as “a three-pillar therapeutic strategy of BRD”. The first 
is an elimination of infectious agents using an appropriate antibacterials, the second is 
modulation of the pulmonary inflammatory reaction and the third – correction of 
mechanical and secretolitic lung disorders.  
However, directly before undertaking of the treatment due to the economic considerations 
and potencial reduction of therapeutic costs, the field cases of the syndrome should be 
classified into four grades: Grade 1, subclinical disease (therapy is usually not necessary); 
Grade 2, compensated clinical disease (at this stage, the inflammatory reaction generated 
tends to limit the impact of the disease on the animal, this clinical form of the disease needs 
mainly antibacterial therapy); Grade 3, noncompensated clinical disease (at this stage, the 
inflammatory reaction is excessive and must be controlled by additional use of anti-
inflammatory drugs); Grade 4, irreversible clinical disease (which threatens the animal’s 
survival, this BRD form is not treated because conceivable profitable effects not compensate 
costs, and affected animals most often die).  
The first element of complex therapeutic strategy of BRD aimed quick pathogenic bacteria 
elimination, particularly these originated from Pasteurellacae family (M. haemolytica, P. 
multocida, H. somni) which as important infectious factors participate in the development of 
pulmonary lesions and dysfunction associated with the syndrome. These bacteria play a 
crucial role in the pathologic cascade: therefore, the antibiotic must be administered as soon 
as possible after the induction of the infection, which is most often clinically characterized 
by hyperthermia, reduced appetite, and nasal discharge. Antibiotic treatment must be 
initiated before irreversible damage (characterized by oral breathing, orthopnea, lactatemia, 
and cyanosis) occurs. Among antibiotics presently used most often are administered long 
acting antibacterials such as some tetracyklines (oxyteracykline), macrolides (florfenicol, 
tulathromycin, gamythromycin) and fluoroquinolones (enrofloxacin, marbofloxacin, 
danofloxacin) with a wider antibacterial spectrum included also mycoplasmas (M. bovis, M. 
bovirhinis, Ureaplasma diversum). Significant role of mycoplasma in BRD etiology is not now 
questioned, and it is especially important because their effective control is very difficult. It is 
generally known that the mycoplasmas are resistant to beta-lactames and cephalosporins 
because of the lack of cell wall. The same resistance can be observed to nalidixic acid, 
polymyxin, rifamycin, tylosin, lincomycin, tylmicosin, trimethoprim and to sulfonamides 
(Poumarat et al., 1996; Ayling et al., 2007). Therefore, in this case there are intensively 
searching new more effective generations of antibiotics against mycoplasma infection. The 
most important mycoplasmal etiological agent in BRD i.e. M. bovis as other mycoplasmas is 
sensitive to antibiotics, which inhibit the protein or nucleic acid synthesis. Recently, in cattle 
respiratory treatment there are recommended antibiotics which were only applied in swine 
medicine i.e. pleuromutilins (tiamulin, valnemulin). At present it is  known too, that 
tiamulin has also excellent activity against cattle mycoplasmas like M. bovis. In addition an 
analog compound of tiamulin is valnemulin, which has proven to be affective in the control 
M. bovis infection under field conditions (Stipkovits et al., 2001; Tenk, 2005).  
Recently, new antibiotic-treatment conceptions of BRD have been presented during the first 
European Buiatrics Forum in Marseille (2009). There were described three independent 
conceptions which in shortening forms are called as SISAAB, SILAAB and MILAAB. The 
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first of them  means: Single Injection Shot Acting AntiBiotic among others things 
represented by new formulations of fluoroquinolones like Marbocyl S (marbofloxacin 100 
mg/ml, administered at a single dose of 8 mg/kg b.w. i.m.), Baytril One or Enroxil Max 
(enrofloxacin 100 mg/ml, administered at a single dose of 7.5 mg/kg b.w. s.c.). Moreover, 
also long acting tetracyclines (Tetradur) could be administered here in a form of single 
intramuscular injections. The second conception is Single Injection Long Acting AntiBiotic 
represented by new generations of macrolides such as tultromycin (Draxxin) and 
gamytromycin (Zactran), and also the third one i.e. Multiple Injection Long Acting 
AntiBiotic which however is considered to be a little controversial conception due to take 
real risks of antibiotic-resistance increasing.  
In the complex of advanced therapeutic strategy of BRD the second its component is the 
modulation of pulmonary inflammatory reaction. In this aspect, at present there are use 
anti-inflammatory medicines originated from both steroidal (SAIDs) and non-steroidal anti-
inflammatory drugs (NSAIDs) (Lekeux, 2006). Steroids are powerful anti-inflammatory 
agents, but their effects on the animal’s defensive machanisms reduce the value of their use 
in syndromes of infectious origin unless they have a short duration of action or are 
administered locally. Generally the drugs stabilise cellular and lysosomal membranes and 
thereby inhibit release of the chemical pro-inflammatory mediators and proteolytic 
enzymes. Other steroidal effects include inhibition of antibody synthesis; suppression of 
activity of fibroblasts; elevation of circulating neutrophil count and reduction in eosinophil 
count. Steroids also increase microvascular tone and decrease permeability thus reducing 
exudation and oedema formation. In BRD adjunctive therapy there were used different 
kinds of corticosteroids include betamethasone (2-10 mg/animal), dexamethasone (2-5 
mg/animal), prednisolone (up to 20 mg/animal), cortisone (up to 500 mg/animal), 
hydrocortisone (up to 300 mg/animal), flumethasone (0.5 mg/animal) and trimcinolone (up 
to 5 mg/animal). The drugs because of their strong immunosupresive character were 
usually use only in a single administration throughout of the therapy.  
In contrast to steroids, which reduce the yield of all products of arachidonic acid cascade, 
nonsteroidal anti-inflammatory drugs (NSAIDs) have a narrower anti-inflammatory spectrum, 
acting as inhibitors of cyclooxygenase. However, NSAIDs have a wider safety margin, which 
largely compensates for their narrower spectrum. NSAIDs act principally to inhibit the 
biosynthesis of prostaglandins. They also inhibit kallikrein activity and kinin formation and at 
the same time pharamacologically antagonise the tissue effects of kinins, prostaglandins and 
slow-reacting substance of anaphylaxis (SRS-A). NSAIDs are, with some exceptions, analgesic 
and antipyretic: effects not shown by steroids. Apart from that NSAIDs have also the ability to 
improve gas exchange what it has been shown in pneumonic calves in experimental 
conditions (Van de Weerdt et al, 1999). The benefits of NSAIDs therapy in bovine respiratory 
disease have also been demonstrated multiple in a field study (Bednarek et al, 2003; Bednarek 
et al, 2004; Lockwood et al 2003; Weingarten, 2009).  
NSAIDs should be administered to animals at grade 3 of severity, which is mainly 
characterized by hyperthermia, anorexia, and dyspnea. NSAIDs act rapidly in the 
pneumonic lung, so the modulation of inflammation and the resulting improvement in the 
clinical status should follow quickly in the absence of irreversible damages (Lekeux, 2006). 
The drugs most commonly used in BRD therapy in Europe are flunixin meglumine (2.2 
www.intechopen.com
 
Bovine Respiratory Syndrome (BRD) Etiopathogenesis, Diagnosis and Control 371 
mg/k b.w. i.v.), carprofen (1.4 mg/kg b.w. i.v., s.c.), ketoprofen (3 mg/kg b.w. i.v., i.m.), 
meloxicam (0.5 mg/kg b.w. s.c., i.v.),  tolfenamic acid (2 mg/kg b.w. i.m.), metamisole 
sodium (10 – 50 mg/kg b.w. i.m., i.v.). 
In the most severe cases of BRD, a short-acting steroidal anti-inflammatory drug, 
bronchodilator, and diuretic could be added to the NSAID when pulmonary fulminating 
infalammation, bronchospasm, and edema are present, respectively. These additional 
supparative drugs i.e. bronchodilators and diuretics are included into the third component 
of the complex therapeutic strategy of BRD. Among bronchodilators mostly atropine sulfate 
(cholinolitics) and theophylline (methylxanthines)  are administered. The first of them is 
classified as an anticholinergic drug (parasympatholytic). In general, atropine lowers the 
parasympathetic activity of all muscles and glands regulated by the parasympathetic 
nervous system. This occurs because atropine is a competitive antagonist of the muscarinic 
acetylcholine receptors (acetylcholine being the main neurotransmitter used by the 
parasympathetic nervous system). Therefore, it may cause bronchictasis and reduced 
secretions salivary, sweat, and mucus glands. As adjuncts in BRD therapy atropine sulfate 
1% is recommended by Lekeux (2002) once a day for three consecutive days at a dose of 0.06 
mg/kg b.w. s.c. Theophylline, also known as dimethylxanthine, as a methylxanthine drugs  
is rarely administered in cattle practice against bronchoconstriction in course of BRD mostly 
intramuscularly or slowly intravenously at a dose of 1-10 mg/kg b.w. However, it is 
recommended in veterinary medicine as bronchodilators in adjuntive therapy for 
respiratory diseases such as BRD, COPD in horses and feline asthma under a variety of 
brand names. Because of its numerous side-effects, the drug is now rarely administered for 
clinical use. As a member of the xanthine family, it bears structural and pharmacological 
similarity to caffeine. 
On the other hand within the veterinary diuretics mostly in calves suffering from severe 
form of BRD caused with pulmonary edema is furosemide (1 mg/kg b.w. i.v.). Furosemide 
(INN) or frusemide (former BAN) is a loop diuretic used in the treatment of congestive heart 
failure and edema. It is most commonly marketed by Sanofi-Aventis under the brand name 
Lasix. It has also been used to prevent Thoroughbred and Standardbred race horses from 
bleeding through the nose during races. 
It should be remember that very important is also to use expectorants (mucolitic drugs) like 
bromhexine hydrochloride (bromhexine HCl) in order to inflammatory mucose evacuation 
from the obturated respiratory airways. Bromhexine is a mucolytic agent used in the 
treatment of respiratory disorders associated with viscid or excessive mucus. In addition, 
bromhexine has antioxidant properties (Morton, 1999). Bromhexine supports the body's 
own natural mechanisms for clearing mucus from the respiratory tract. It is secretolytic: that 
is, it increases the production of serous mucus in the respiratory tract and makes the phlegm 
thinner and less sticky. This contributes to a secretomotoric effect: it helps the cilia - tiny 
hairs that line the respiratory tract - to transport the phlegm out of the lungs. For this reason 
at present it is generally recommended as a adjunct in the complex therapy of BRD. In 
clinical studies, bromhexine showed secretolytic and secretomotoric effects in the bronchial 
tract area which facilitates expectoration and eases cough. It is indicated as “secretolytic 
therapy in bronchopneumonia of calves associated with abnormal mucus secretion, 
impaired mucus transport and bromhexine has also antiinflammatory properties” 
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(Bednarek & Kondracki, 2002). Bromhexine also enhances mucus transport by reducing 
mucus viscosity and by activating the ciliated epithelium. Bromhexine is contained in 
various formulations (high and low strength syrups, tablets intended mainly for companies 
animals), however in cattle practice the most useful form is injectable preparation (Eres, 
Bisolvon, Bisolvomicin, Flegamina) recommended in affected calves at a dose of 0.5 mg/kg 
b.w. i.m. for 5 to 7 consecutive days. Bromhexine is a well established and well tolerated 
product in its indication.  
Other expectorants have been used too in chronic cases of coughing in course of BRD 
(Andrews, 2004). These include a mixture of strychnine hydroxide, arsenic trioxide and 
ferric ammonium citrate given at a dose of about 5 ml orally twice daily, or 
diphenhydramine hydrochloride, ammonium chloride, sodium citrate and menthol at 5-10 
ml orally two or three times daily. There is limited benefit form the antihistaminic action of 
diphenhydramine hydrochloride in cases of calf pneumonia. This resent indication has been 
accepted too but many clinicians consider that using antihistamines is a little effective in calf 
bronchopneumonia. This is probably because the main proinflammatory mediator of cattle 
is not histamine like and human and other mammals but 5-HT (5-hydroxytryptamine). The 
histamine that is released occurs very quickly following the antibody-antigen reaction so 
that antihistamines can only be of use in the early stages of the inflammatory response. 
Among of the drugs in USA recently for the large animal medicine (horses, cattle) are used 
tripelennamine hydrochloride at a dose of 1 mg/kg b.w. i.m. once a day (Divers, 2011). The 
dose may be repeated in 6 to 12 hours if necessary. 
Presented above the basic principles and drugs used for the optimal therapeutic strategy of 
BRD especially within Grade 3 of the disease are very important to maintain the profitability 
of cattle breading. This strategy is a combination of an antibiotic acting against the relevant 
pathogens (eg. florfenicol) and an NSAID acting against the deleterious effects of 
inflammation (eg, flunixin) additionally supported  by the correctors of mechanical and 
secretolitic lung disorders (Expectorants, bronchodilators). This strategy were confirmed by 
several experimental and field tests showing an improvement of clinical signs and a 
reduction of pulmonary dysfunction and lung consolidation in animals receiving such a 
combined therapy. 
In the complex control measures of BRD should be added too about prevention using 
vaccination programmes. There are various vaccines available both live or attenuated 
consist of only one or a few bacterial or/and viral antigens. Dead vaccines are used to 
provide immunity against P. multocida and septicemic and pneumonic strains of M. 
haemolytica and H. somni (eg, Hiprabovis pneumos, Pastobov, Bovilis Bovipast). Killed or 
modified live polyvalent vaccines are used in many  countries and also in Poland, and 
contain antigens such as BRSV, PI3 (Rispoval, Bovilis Bovipast), BVDV (Mucosiffa, Bovilis 
BVD) and BHV1. Recently the last presented antigen  is widely utilized in the construction 
of so-called marker vaccines both live (eg, Rispoval-IBR marker vivum, Hiprabovis-IBR 
marker live) and inactivated (eg, Ibraxion, Rispoval-IBR-marker inactivatum, Bovilis IBR – 
marker inactivatum) applied in IBR eradication based on DIVA system i.e. Differentiating 
Infected from Vaccinated Animals. The vaccines are usually administered parenterally and 
usually require two injections to produce immunity. Recent developments have included 
combined live and dead viral components of the four main antigens which are injected 
intramuscularly (eg, Rispoval 3). When live vaccines are used, the integrity of the vaccine 
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must ensure absence of other potential contaminats, both viral and other pathogens. 
Subsequently, modified live intranasal vaccines have been available (eg. Rispoval RS+PI3 
IntraNasal). Till now numerous studies have demonstrated that immunization calves via the 
intranasal route not only is most effective and it gives active immunity in very young 
animals despite maternal antibodies, it also generates a significant systemic response and 
interferon induction (Stokes, 2006). Given the relative ease of antigen delivery and the 
organization of the local lymphoid tissue (MALT), intranasal immunization offers attractive 
possibilities. However, to successfully achieve this there are a number of obstacles that have 
to be overcome. For example in the context of IBR vaccination, sometimes, although good 
immunity was conferred to animals by modified live vaccination, it was shown that some 
cattle became carriers  after exposure to field strains of BHV.  
In multifactorial etiology of BRD at present there is also valued the role of mycoplasmal 
infectious agents. Therefore, many scientific centers all over the world try to produce 
suitable vaccines mainly against the most important mycoplasma  i.e. M. bovis. Till now in 
Europe the saponin inactivated vaccine has been produced in the UK (by The Mycoplsma 
Group, AHVLA in Webridge), but it has had only limited success experimentally. The 
inactivated vaccine containing saponin-killed cells was shown to be safe, highly 
immunogenic and protective against a strong experimental challenge with virulent M. bovis 
(Nicholas et al., 2002). Vaccinated calves showed few respiratory signs while all 
unvaccinated calves developed signs of pneumonia. Moreover, vaccination gave a 
statistically significant degree of protection against pyrexia, lung lesions and loss of body 
weight. The vaccine also reduced the spread of M. bovis to internal organs, including the 
joints. This vaccine is now under commercial development and AHVLA (Weybridge) has a 
licence to produce this as an autogenous vaccine in the UK. Therefore, practically no 
commercial vaccines currently exist for M. bovis in Europe. Various commercial vaccines, 
including autogenous preparations, are available in the USA; however there is no published 
evidence to support their effectiveness.  
Recapitulating, the control of the Bovine respiratory syndrome is essential to maintain the 
profitability of most intensive bovine ventures, and veterinary practitioners have the 
opportunity to play an important role in this effort. Preventive and therapeutic measures 
must be adapted to the type of production operation, the specific features associated with 
the individual animal, the environment and the pathogens, the availability of drugs, and the 
state of the art in science.   
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